Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilumya with or without Halog in Plaque Psoriasis
NCT04347473Phase 4
Key facts
- Status
- Recruiting
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Countries
- 1
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Modality
- Monoclonal Antibodies
- Drugs
- tildrakizumab
- Conditions
- plaque psoriasis
01
Overview
Phase 4, open-label, single-arm trial of tildrakizumab in plaque psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Primary endpoint: Body Surface Area at 16 weeks. Started Apr 2020; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Ilumya
All patients receive Ilumya. Halog added conditionally.
03
Who it enrols
Adult patients with moderate-to-severe chronic plaque psoriasis (BSA >= 10%, PGA >= 3, PASI >= 12) who are candidates for phototherapy or systemic therapy. Excludes patients with active or untreated latent tuberculosis.
04
Endpoints
Primary
Body Surface Area
Beyond the preview
Go deeper on NCT04347473.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347473.